Cargando…

A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature

In two articles published in Science online in September 2020, Zhang et al. [1] and Bastard et al. [2] elucidated a key factor in the progression to severe COVID-19; namely, a deficiency in interferon, especially type I interferon (IFN I). This deficiency might be caused by diverse reasons such as g...

Descripción completa

Detalles Bibliográficos
Autor principal: Fang, Xiangming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Publishing Services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801063/
http://dx.doi.org/10.1016/j.fmre.2022.01.005
_version_ 1784642373358190592
author Fang, Xiangming
author_facet Fang, Xiangming
author_sort Fang, Xiangming
collection PubMed
description In two articles published in Science online in September 2020, Zhang et al. [1] and Bastard et al. [2] elucidated a key factor in the progression to severe COVID-19; namely, a deficiency in interferon, especially type I interferon (IFN I). This deficiency might be caused by diverse reasons such as genetic mutations of genes encoding key antiviral signaling molecules, or the ‘neutralization’ of IFN I by endogenous antibodies. How does IFN I deficiency cause severe, life-threatening COVID-19? The most straightforward explanation is that such deficiency allows uncontrolled virus replication and spread. IFN I deficiency may also have other impacts on immune system function. Individuals with mutations in the IFN-I-induced signaling pathways may benefit from interferon therapies. In addition, individuals with neutralizing antibodies against IFN-α and IFN-ω may also benefit from other types of interferons provided in the therapy, such as IFN-β and IFN-λ.
format Online
Article
Text
id pubmed-8801063
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Publishing Services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-88010632022-01-31 A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature Fang, Xiangming Fundamental Research Commentary In two articles published in Science online in September 2020, Zhang et al. [1] and Bastard et al. [2] elucidated a key factor in the progression to severe COVID-19; namely, a deficiency in interferon, especially type I interferon (IFN I). This deficiency might be caused by diverse reasons such as genetic mutations of genes encoding key antiviral signaling molecules, or the ‘neutralization’ of IFN I by endogenous antibodies. How does IFN I deficiency cause severe, life-threatening COVID-19? The most straightforward explanation is that such deficiency allows uncontrolled virus replication and spread. IFN I deficiency may also have other impacts on immune system function. Individuals with mutations in the IFN-I-induced signaling pathways may benefit from interferon therapies. In addition, individuals with neutralizing antibodies against IFN-α and IFN-ω may also benefit from other types of interferons provided in the therapy, such as IFN-β and IFN-λ. The Authors. Publishing Services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. 2022-03 2022-01-30 /pmc/articles/PMC8801063/ http://dx.doi.org/10.1016/j.fmre.2022.01.005 Text en © 2022 The Authors. Publishing Services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Commentary
Fang, Xiangming
A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature
title A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature
title_full A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature
title_fullStr A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature
title_full_unstemmed A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature
title_short A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature
title_sort commentary of “type i interferon deficiency can lead to severe covid-19” in 10 remarkable discoveries from 2020 in nature
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801063/
http://dx.doi.org/10.1016/j.fmre.2022.01.005
work_keys_str_mv AT fangxiangming acommentaryoftypeiinterferondeficiencycanleadtoseverecovid19in10remarkablediscoveriesfrom2020innature
AT fangxiangming commentaryoftypeiinterferondeficiencycanleadtoseverecovid19in10remarkablediscoveriesfrom2020innature